Lv1
36 积分 2023-12-11 加入
Global patterns and trends in breast cancer incidence and mortality across 185 countries
1天前
已完结
Reversible HER2 antibody-drug conjugate–induced ocular toxicity
4天前
已完结
Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
27天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
1个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Not out of the woods: perspectives from patients with triple-negative breast cancer
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases
1个月前
已完结
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
